GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Delcath Systems Inc.
Delcath Systems produces a system for targeted liver chemotherapy. Its stock price is extremely volatile, reflecting the long and arduous path to FDA approval. The chart tells the story of patients' and investors' hopes for this new cancer treatment.
Share prices of companies in the market segment - Cancer cure
Delcath Systems has developed and commercialized the CHEMOSAT® system for regional perfusion chemotherapy for the treatment of liver cancer. We classify it under the "Cancer Treatment" sector. The chart below shows the overall dynamics of this highly specialized oncology segment.
Broad Market Index - GURU.Markets
Delcath Systems is an oncology company that has developed a system for targeted delivery of high-dose chemotherapy directly to the liver. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Delcath's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
DCTH - Daily change in the company's share price Delcath Systems Inc.
The daily price change of Delcath, an oncology company, reflects the high risks of the biotech sector. Change_co shows the sensitivity to sales of its liver cancer treatment system. This metric is the basis for analysis of the oncology medical equipment sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer cure
Delcath Systems, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the dynamics of DCTH, which focuses on liver cancer treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Delcath is an oncology company that has developed a system for localized liver chemotherapy. The biotech sector is extremely volatile, and Delcath's story is a prime example. The chart below reflects the average fluctuations in this industry, providing context for the company's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Delcath Systems Inc.
For Delcath Systems, the year-over-year performance represents the culmination of a multi-year battle to secure approval for its liver cancer treatment system. Its market capitalization change over the past 12 months reflects FDA approval and the initial commercialization phase, a fundamental milestone that transforms the company from an R&D company into a commercial enterprise.
Annual dynamics of market capitalization of the market segment - Cancer cure
Delcath Systems, Inc. is a commercial-stage medical device company specializing in the treatment of liver cancer. Its success depends on the commercialization of its unique chemotherapy delivery system. This chart illustrates how its niche strategy and regulatory decisions impact its volatile performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Delcath is a biopharmaceutical company whose stock performance is driven by the commercialization of its cancer treatments and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Delcath Systems Inc.
Delcath, a healthcare company, depends on its product cycle for its market value. Monthly fluctuations on the chart reflect the commercial launch of its liver cancer treatment system, the success of which determines its future, making the stock highly news-sensitive.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Delcath Systems, Inc. is a specialized oncology company that has developed a unique system for delivering high-dose chemotherapy directly to the liver. The dynamics of its sector, shown in the graph, reflect the risks and promises of cancer treatment. Against this backdrop, it's possible to assess how the commercialization of its niche technology for the treatment of liver metastases impacts its future.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Delcath Systems, a cancer treatment company, belongs to the biotech sector, where stocks react to specific events. The chart below illustrates how the company's monthly price fluctuations are driven not by general market sentiment, but by news about clinical trials, regulatory approvals, and commercial product launches.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system for liver cancer. Its weekly stock price reflects the pace of commercialization of its product, insurance company reimbursement decisions, and news about clinical applications.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Delcath, like other companies in the innovative medical equipment sector, is dependent on general factors such as the pace of new technology adoption in hospitals and insurance company policies. The chart compares the company's performance with the overall health of its medical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Delcath Systems has developed a treatment for liver cancer. As a medical technology company, it should be less dependent on the economy. The chart will show how insulated its shares are from market fluctuations, moving in sync with news about the implementation of its technology in hospitals, rather than driven by macroeconomic data.
Market capitalization of the company, segment and market as a whole
DCTH - Market capitalization of the company Delcath Systems Inc.
The chart of Delcath Systems reveals the perilous story of the battle for medical device approval. Its market cap reflects the company's long and arduous journey to gain FDA approval for its liver metastasis treatment system. It's a visual representation of perseverance in the world of biotech.
DCTH - Share of the company's market capitalization Delcath Systems Inc. within the market segment - Cancer cure
Delcath Systems, Inc. has established its market share by developing a unique system for targeted chemotherapy of liver metastases. Its market capitalization reflects its status as a niche player with breakthrough technology for the treatment of certain cancer types.
Market capitalization of the market segment - Cancer cure
Delcath Systems offers targeted liver chemotherapy. What is the size of this niche? The graph below shows the overall market capitalization of the cancer treatment sector. Its growth reflects the ongoing search for new, more effective, and less toxic treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Delcath Systems chart visualizes the struggle for approval and adoption of a niche cancer treatment. The market capitalization of the company, whose product delivers chemotherapy directly to the liver, reflects the long and arduous journey from clinical trials to commercialization. This is a diagram of persistence in oncology.
Book value capitalization of the company, segment and market as a whole
DCTH - Book value capitalization of the company Delcath Systems Inc.
Delcath Systems' assets include its manufacturing facilities for the liver chemotherapy system, as well as its R&D infrastructure. Its book value reflects the value of these specialized medical assets. The chart below shows how the company has invested in its manufacturing and research capital.
DCTH - Share of the company's book capitalization Delcath Systems Inc. within the market segment - Cancer cure
Delcath Systems, Inc. is fighting liver cancer. Its tangible assets are the production lines used to create its unique chemotherapy system. These facilities are a physical source of hope for patients. The graph shows the share of its manufacturing base in the niche but important oncology medical equipment sector.
Market segment balance sheet capitalization - Cancer cure
Delcath Systems produces a system for treating liver cancer. The medical equipment sector, as the chart shows, is capital-intensive. Delcath is a niche player. Its business consists of R&D and production of a unique chemotherapy device.
Book value of all companies included in the broad market index - GURU.Markets
Delcath Systems' assets include manufacturing facilities for their liver-targeted chemotherapy system. The chart below shows how the company has built its resources to commercialize this unique medical device.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Delcath Systems Inc.
Delcath's book value is its manufacturing capacity. But investors see more than just hardware; they see a targeted chemotherapy technology that offers hope to patients with difficult-to-treat cancer. The premium to its book value is a direct reflection of this hope and the life-saving potential of their system. The chart below is a history of market confidence, which soared on FDA news and plummeted on setbacks.
Market to book capitalization ratio in a market segment - Cancer cure
Delcath Systems has developed a system for targeted chemotherapy for liver cancer. Its value lies in this unique medical technology. The chart shows how its market capitalization, based on commercial potential, relates to its current assets.
Market to book capitalization ratio for the market as a whole
Delcath Systems has developed a system for treating liver cancer metastases. Its valuation, unlike the average in this chart, is based on its unique and approved medical technology. The market evaluates its commercial potential and the ability to make its procedure a standard of care for a specific group of cancer patients.
Debts of the company, segment and market as a whole
DCTH - Company debts Delcath Systems Inc.
Delcath Systems has developed a specialized system for the treatment of liver metastases. This chart shows the company's financial journey, which has been a long one, leading to commercialization of its product. Raising capital was necessary to fund clinical trials and obtain FDA approval, which is typical for medical device companies.
Market segment debts - Cancer cure
Delcath Systems has developed a targeted chemotherapy system for the treatment of liver cancer. The company is in the commercialization phase of its product. This chart shows how its leverage reflects the enormous costs of obtaining regulatory approval and ongoing investments in marketing and physician training to implement this complex procedure into clinical practice.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Delcath Systems Inc.
Delcath Systems is a medical device company that has developed a system for treating liver cancer. Bringing such specialized equipment to market requires significant capital. This chart shows the company's reliance on debt to finance its commercialization and production, a key indicator of its financial strength.
Market segment debt to market segment book capitalization - Cancer cure
Delcath Systems has developed a targeted chemotherapy system for liver cancer. This chart shows the debt burden in the oncology equipment sector. It helps understand how the company finances the commercialization of its unique medical device and its clinical implementation.
Debt to book value of all companies in the market
Delcath Systems offers specialized treatment for liver cancer. Bringing highly specialized medical products to market requires significant investments in marketing and physician training. This graph of total market debt helps us understand how aggressively the company is willing to leverage debt to commercialize its unique technology.
P/E of the company, segment and market as a whole
P/E - Delcath Systems Inc.
Delcath Systems has developed a system for isolated liver chemotherapy for certain types of cancer. This chart shows how investors value this medical device for niche oncology applications. Its performance depends entirely on the system's commercial success following FDA approval and its acceptance by oncologists.
P/E of the market segment - Cancer cure
Delcath Systems has developed and commercialized a liver perfusion system that delivers high doses of chemotherapy directly to the affected organ while minimizing side effects. This chart shows the average rating for the oncology sector, reflecting how the market values innovative cancer treatments, especially in advanced stages.
P/E of the market as a whole
Delcath Systems produces a system for isolated liver chemotherapy for certain types of cancer. Its valuation depends entirely on the commercial success of this highly specialized product. General market sentiment, reflected in this chart, is irrelevant compared to sales data and the adoption of its technology by oncologists.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Delcath Systems Inc.
Delcath Systems, Inc. has developed a regional chemotherapy system that delivers high doses of the drug directly to the affected organ (e.g., the liver). This schedule reflects expectations for the commercialization of this specialized oncology procedure. Evaluation is dependent on physician acceptance and reimbursement from insurance companies.
%20P%2FE%20Delcath%20Systems%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Delcath-Systems-Inc.&v=1772513567156 "Chart of the company's future (projected) P/E Delcath Systems Inc.")
Future (projected) P/E of the market segment - Cancer cure
Delcath Systems has developed a targeted chemotherapy system that isolates the liver to deliver high doses of the drug for the treatment of certain cancers. This chart reflects expectations for the commercialization of this highly specialized technology. Comparing these forecasts with the sector reveals how investors assess its potential in the oncology market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513567175 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Delcath Systems has developed a targeted chemotherapy system for the treatment of liver cancer. This is a niche medical technology. Amid the general market fluctuations shown by this chart, Delcath's story is a bet that its unique treatment method will be accepted by the medical community for a specific group of patients.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513567212 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Delcath Systems Inc.
Delcath Systems, Inc. is an oncology company specializing in the treatment of liver cancer. Its key product is a regional chemotherapy system. The company's profitability depends on the commercial success of this system and its adoption in cancer centers. This chart shows the path to profitability in the specialized medical equipment market.
Profit of companies in the market segment - Cancer cure
Delcath Systems has developed a targeted chemotherapy system that isolates the liver to deliver high doses of the drug for the treatment of certain types of cancer. This is a highly specialized medical product. The profitability chart in the cancer treatment sector shows how innovative methods targeting difficult-to-treat diseases are finding their niche and impacting the overall oncology landscape.
Overall market profit
Delcath Systems has developed a targeted chemotherapy system that delivers high doses of the drug directly to the affected organ (for example, the liver). This technology has the potential to significantly improve treatment outcomes for certain types of cancer. The company's growth depends on its clinical implementation and is an example of innovation in oncology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system for liver cancer. This graph shows the expected commercialization of this niche medical technology. Future revenue depends on the acceptance of this procedure by oncologists and insurance reimbursement.
%20profit%20of%20the%20company%20Delcath%20Systems%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Delcath-Systems-Inc.&v=1772513567320 "Graph of future (projected) profit of the company Delcath Systems Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Delcath Systems, Inc. has developed a regional chemotherapy system designed to treat liver metastases. The forecast chart reflects revenue expectations for the medical technology sector. It allows one to assess the market potential of the company's specialized cancer treatment method against the backdrop of overall industry trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513567392 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
This chart illustrates the expectations of a medical company specializing in the treatment of liver cancer. Delcath Systems' revenue forecast depends on the successful commercialization of its targeted chemotherapy system. Regulatory approval and adoption of the technology by cancer centers are critical to the company's future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513567453 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system for liver cancer. This chart shows how investors estimate its revenue at the commercialization stage. The multiple reflects expectations regarding the widespread adoption of its technology in oncology practice.
P/S market segment - Cancer cure
Delcath Systems has developed a targeted chemotherapy system for the treatment of liver cancer. The company's revenue depends on the adoption of this specialized medical procedure in oncology centers. This chart shows the average valuation in the sector, allowing investors to assess how highly the market values Delcath's potential to generate revenue in its narrow but important niche.
P/S of the market as a whole
Delcath Systems has developed a targeted chemotherapy system that delivers high doses of the drug directly to the liver to treat certain types of cancer. This graph, showing Delcath's average revenue estimate, helps understand how investors view the potential of this niche medical technology and its path to commercial success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system for the treatment of liver cancer. The company's future revenue depends on the successful commercialization of this system in the US and Europe. This chart shows how investors assess the potential of this niche oncology product and the company's ability to convince doctors and hospitals of its effectiveness.
%20P%2FS%20Delcath%20Systems%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Delcath-Systems-Inc.&v=1772513567519 "The graph of the company's future (projected) P/S Delcath Systems Inc.")
Future (projected) P/S of the market segment - Cancer cure
Delcath Systems has developed a localized chemotherapy system designed to treat liver cancer. This chart compares market expectations for its future revenue with those of other companies working on cancer treatments. The valuation reflects investor expectations for the commercial success of this niche oncology procedure.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513567523 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Delcath Systems has developed a targeted chemotherapy system for liver cancer. The company's growth depends on the acceptance of this technology by oncologists and regulatory approval. Delcath's success exemplifies how innovations in medical devices can improve treatment outcomes and create new markets, as illustrated in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513567549 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Delcath Systems Inc.
Delcath Systems manufactures and markets a system for isolated liver chemotherapy for patients with metastatic disease. This chart shows revenue from sales of these specialized medical devices to hospitals, demonstrating the adoption of this niche cancer treatment method in clinical practice.
Sales of companies in the market segment - Cancer cure
Delcath Systems, Inc. has developed the CHEMOSAT system, designed for isolated liver perfusion with high-dose chemotherapy for the treatment of metastatic ocular melanoma. It is a niche but vital product. This chart shows overall sales in the sector, illustrating how highly specialized technologies can address complex medical challenges untreatable with standard therapies.
Overall market sales
Delcath Systems has developed a targeted chemotherapy system that isolates the liver and delivers high doses of the drug to treat metastases. This overall economic activity schedule impacts Delcath through the budgets of cancer centers. The implementation of new, complex, and expensive procedures depends on the financial health of the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system for the treatment of liver cancer. The company's future revenue depends on the commercial success of this specialized medical procedure. This chart shows analysts' forecasts for the adoption of this technology in oncology practice and its scope of application.
%20sales%20of%20the%20company%20Delcath%20Systems%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Delcath-Systems-Inc.&v=1772513567620 "Schedule of future (projected) sales of the company Delcath Systems Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Delcath Systems, Inc. has developed a system for localized chemotherapy for the treatment of liver cancer. This chart shows projected revenue for the entire medical device sector. While it reflects general trends, Delcath prioritizes regulatory approvals and the acceptance of its niche technology by oncologists.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513567628 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Delcath Systems has developed a targeted chemotherapy system for liver cancer. Demand for its product depends on regulatory approval and the willingness of cancer centers to implement this complex new procedure. This timeline, reflecting the state of the economy, impacts hospital budgets and their ability to invest in innovative, yet expensive, treatments, which is key to Delcath's commercial success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513567692 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Delcath Systems Inc.
Delcath Systems has developed a specialized system for treating liver cancer. This graph shows the medical company's financial trajectory during the commercialization phase. Profitability depends on how quickly its unique therapy is adopted by the medical community, which requires significant investment in physician training and marketing.
Market segment marginality - Cancer cure
Delcath Systems has developed a targeted chemotherapy system that delivers high doses of the drug directly to the liver to treat certain types of cancer. This chart shows the company's operational structure at the commercialization stage of its niche product. It reflects its marketing and manufacturing costs compared to other companies in the oncology sector.
Market marginality as a whole
Delcath Systems has developed a system for treating metastatic eye cancer that has spread to the liver. The company's profitability depends on the adoption of this specialized procedure by cancer centers. This total market return chart highlights Delcath's position in a niche medical field, where the effectiveness of its therapy in treating a rare and fatal disease is key to success.
Employees in the company, segment and market as a whole
Number of employees in the company Delcath Systems Inc.
Delcath Systems has developed a targeted chemotherapy system that delivers high doses of the drug directly to the liver for cancer treatment. This graph shows the team working on commercializing this niche product. Staff growth will be directly dependent on success in obtaining approvals and implementing this complex procedure in clinics.
Share of the company's employees Delcath Systems Inc. within the market segment - Cancer cure
This figure reflects Delcath Systems' focused approach. The company's oncology team is focused on commercializing its system for treating metastatic ocular cancer (uveal melanoma) to the liver. This team offers a highly specialized procedure for patients with very limited treatment options for this rare disease.
Number of employees in the market segment - Cancer cure
Delcath Systems has developed a targeted chemotherapy system that delivers high doses of the drug directly to the affected organ (such as the liver), minimizing side effects. This graph illustrates how innovations in oncology are aimed at improving the effectiveness and safety of treatment, requiring new equipment and skills from physicians.
Number of employees in the market as a whole
Delcath Systems, Inc. has developed a system for targeted liver chemotherapy. Its market is oncology clinics. Demand for its products is determined by the effectiveness of treatments and their approval, not by the economic situation, as shown in this graph. The company offers a unique solution to a complex medical problem.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Delcath Systems Inc. (DCTH)
Delcath Systems developed a system for targeted liver chemotherapy. This chart shows how the market values this highly specialized medical device. The high market capitalization per employee indicates the company's focus on intellectual property and clinical data, resulting in a high valuation despite its relatively small team.
%20of%20the%20company%20Delcath%20Systems%20Inc.%20(DCTH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Delcath-Systems-Inc.-DCTH&v=1772513568165 "Chart of market capitalization per employee (in thousands of dollars) of the company Delcath Systems Inc. (DCTH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Delcath Systems has developed a targeted chemotherapy system for liver cancer. For a company with a single key product, this metric reflects its market potential. The chart shows how investors assess the prospects of this unique technology and its ability to carve out a niche in oncology.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513568180 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Delcath Systems, Inc. has developed a system for isolated liver chemotherapy for the treatment of metastatic cancer. This chart for the medtech company reflects the market valuation of its unique product. The high cost per employee is driven by the potential of this technology to become a standard of care for a specific group of cancer patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513568213 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Delcath Systems Inc. (DCTH)
Delcath Systems (DCTH) is a medical technology company that developed the CHEMOSAT system for regional chemotherapy (delivering a high dose of chemotherapy directly to the affected organ, such as the liver). This graph shows how successfully the company is commercializing this complex procedure. Revenue per employee will increase if clinics begin using it on a large scale.
%20Chart%20Delcath%20Systems%20Inc.%20(DCTH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Delcath-Systems-Inc.-DCTH&v=1772513568253 "Company Profit Per Employee (in thousands of dollars) Chart Delcath Systems Inc. (DCTH)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Delcath Systems produces a liver chemotherapy system (CHEMOSAT), isolating the liver from the rest of the bloodstream. It is a highly specialized medical device for cancer treatment. This chart shows how effectively the company is monetizing this complex procedure. It serves as a benchmark for assessing how successfully Delcath is bringing its niche oncology product to market.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513568300 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Delcath Systems (DCTH) is an oncology company that developed the CHEMOSAT system for delivering high doses of chemotherapy directly to the liver (for the treatment of metastases). It's a niche medical device. This graph (likely unprofitable) shows their path to commercialization. R&D and approval costs are high. Growth will begin when clinics begin actively using their expensive procedure.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513568315 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Delcath Systems Inc. (DCTH)
Delcath Systems has developed a system for regional chemotherapy aimed at treating liver cancer. This chart shows how the company is commercializing its highly specialized medical technology. Revenue per employee growth will depend on its implementation in cancer centers.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Delcath-Systems-Inc.-DCTH&v=1772513568337 "Sales chart per company employee Delcath Systems Inc. (DCTH)")
Sales per employee in the market segment - Cancer cure
Delcath Systems specializes in treating cancer, specifically liver metastases, with its targeted chemotherapy system. This chart shows the average revenue per employee in the segment, demonstrating how productive their team is in commercializing this complex medical procedure.
Sales per employee for the market as a whole
Delcath Systems is a medical company specializing in liver cancer treatment. They developed the CHEMOSAT system, which delivers a high dose of chemotherapy directly to the liver, isolating it from the rest of the body. This graph shows how their R&D and sales teams generate revenue from this complex, niche procedure.
Short shares by company, segment and market as a whole
Shares shorted by company Delcath Systems Inc. (DCTH)
Delcath Systems is a medical device company whose system delivers high doses of chemotherapy directly to the liver (for the treatment of metastases). The bearish sentiment seen in this chart may be due to concerns about its commercial success. The bearish sentiment suggests that this is a niche procedure, and the company will have a difficult time convincing hospitals to implement it.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Delcath-Systems-Inc.-DCTH&v=1772513568438 "Short Shares Chart for the Company Delcath Systems Inc. (DCTH)")
Shares shorted by market segment - Cancer cure
Delcath Systems produces a liver chemoperfusion system—a method for delivering high doses of chemotherapy directly to the affected organ in cases of metastases. This chart reflects the overall sentiment in the sector. It reflects investor concerns about the slow adoption of complex and expensive oncology procedures in hospitals.
Shares shorted by the overall market
Delcath Systems (DCTH) is a medical company whose device delivers chemotherapy directly to the liver. It's a highly specialized product. This chart measures overall market pessimism. During periods of panic, investors are less likely to understand niche medical technologies and may sell DCTH shares simply due to their low liquidity.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Delcath Systems Inc. (DCTH)
Delcath Systems is a manufacturer of a medical device for targeted chemotherapy for liver cancer. It's a niche medtech company. This chart measures how investors view the commercial launch of their system. It shows when the stock is overbought on sales growth expectations or oversold on disappointment.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Delcath-Systems-Inc.-DCTH&v=1772513568499 "RSI 14 indicator chart for the company's stock Delcath Systems Inc. (DCTH)")
RSI 14 Market Segment - Cancer cure
Delcath Systems is an oncology company that developed the CHEMOSAT system, a medical device that delivers high-dose chemotherapy directly to the liver for the treatment of metastases. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Delcath Systems (DCTH) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DCTH (Delcath Systems Inc.)
Delcath (DCTH) has developed a chemotherapy system that isolates the liver to deliver high doses of medication for cancer (ocular melanoma). This chart shows the median target price. It reflects the collective opinion of analysts on the commercial success of this niche oncology procedure and the pace of its clinical adoption.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DCTH-Delcath-Systems-Inc.&v=1772513568588 "A chart showing analyst consensus forecasts for the expected stock price. DCTH (Delcath Systems Inc.)")
The difference between the consensus estimate and the actual stock price DCTH (Delcath Systems Inc.)
Delcath (DCTH) is a medtech company that developed the unique CHEMOSAT system. It delivers ultra-high doses of chemotherapy directly to the liver (for the treatment of metastases). This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the commercial potential of this niche technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DCTH-Delcath-Systems-Inc.&v=1772513568621 "A chart showing the difference between the consensus forecast and the actual stock price. DCTH (Delcath Systems Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Delcath Systems (DCTH) is an oncology company that developed the unique Hepzato system, which "isolates" the liver and delivers an ultra-high dose of chemotherapy. This chart shows general expectations for the cancer treatment sector, reflecting whether experts believe there will be demand for this complex yet effective procedure.
Analysts' consensus forecast for the overall market share price
Delcath Systems is a biotech company specializing in liver cancer treatment. Their technology (CHEMOSAT) allows for the isolation of the liver and its "washing" with a high dose of chemotherapy. This chart shows overall market sentiment. For Delcath, commercializing a complex medical procedure, it's important to understand how these expectations (hospital budgets) impact its adoption. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Delcath Systems Inc.
Delcath is the company behind a unique chemofiltration system (HEPZATO KIT). Their system delivers ultra-high doses of chemotherapy exclusively to the liver (for cancer treatment) and then purifies the blood, reducing toxicity. This graph is a barometer of their launch, likely reflecting the pace of adoption of this complex yet groundbreaking procedure in cancer centers.
AKIMA Market Segment Index - Cancer cure
Delcath (DCTH) is a medtech innovator in oncology; the company produces the CHEMOSAT system, which delivers ultra-high doses of chemotherapy directly to the liver for cancer treatment via organ isolation. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough technology (DCTH) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Delcath Systems is an interventional oncology company focused on the treatment of liver cancer. Its key product is the HEPZATO chemotherapy delivery system. This chart, reflecting the market average, provides context. It helps assess how this commercialization of a niche medical device compares to overall economic trends.
